항정신병약물 임상의 역사와 미래

참고문헌 (90)

1. Ahonen M, "Mental Disorders in Ancient Philosophy", pp.28~29 (2014), Spinger International Publishing
2. Baumeister AA, "Continuity and discontinuity in the historical development of modern psychopharmacology", J Hist Neurosci, 14, pp.199~209 (2005)
3. Baldessarini RJ, "Commentary : the current state of psychopharmacology and psychiatry", Rev Psiquiatr Salud Ment, 4, pp.5~8 (2011)
4. Lehmann HE, "Before they called it psychopharmacology", Neuropsychopharmacology, 8, pp.291~303 (1993)
5. Lehmann HE, "The history of the psychopharmacology of schizophrenia", Can J Psychiatry, 42, pp.152~162 (1997)
6. Luigjes J, "Surgery for psychiatric disorders", World Neurosurg, 80, pp.S31.e17~S31.e28 (2013)
7. Robison RA, "Surgery of the mind, mood, and conscious state : an idea in evolution", World Neurosurg, 80, pp.S2~S26 (2013)
8. López-Muñoz F, "History of the discovery and clinical introduction of chlorpromazine", Ann Clin Psychiatry, 17, pp.113~135 (2005)
9. Kunz E, "Henri Laborit and the inhibition of action", Dialogues Clin Neurosci, 16, pp.113~117 (2014)
10. Hamon J, "Effect of R. P. 4560 on maniacal agitation", Ann Med Psychol(Paris), 110, pp.331~335 (1952)
11. Carpenter WT Jr, "Another view of the history of antipsychotic drug discovery and development", Mol Psychiatry, 17, pp.1168~1173 (2012)
12. Lehmanne HE, "Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states", Arch Neurol Psychiatry, 71, pp.227~237 (1954)
13. Delay J, "Chlorpromazine and neuroleptic treatments in psychiatry", J Clin Exp Psychophatol, 17, pp.19~24 (1956)
14. Delay J, "Cas de psychoses traitées par la cure prolongée et continue de 4560 RP. CR 50e Congrès des aliénistes et neurol", de Langue Fse, 38, pp.503~513 (1952)
15. Moncrieff J, "An investigation into the precedents of modern drug treatment in psychiatry", Hist Psychiatry, 10, pp.475~490 (1999)
16. Granger B, "The haloperidol story", Ann Clin Psychiatry, 17, pp.137~140 (2005)
17. Divry P, "Le R1625, nouvelle thérapeutique symptomatique de l’agitation psychomotrice", Acta Neurol Psychiatr Belg, 58, pp.878~888 (1958)
18. Divry P, "Report on the neuropsycho-pharmacological activity of haloperidol (R 1625)", Acta Neurol Psychiatr Belg, 60, pp.7~19 (1960)
19. Divry P, "Study & clinical trial of R 1625 or haloperidol, a new neuroleptic & so-called neurodysleptic agent", Acta Neurol Psychiatr Belg, 59, pp.337~366 (1959)
20. Deniker P, "Experimental neurological syndromes and the new drug therapies in psychiatry", Compr Psychiatry, 1, pp.92~102 (1960)
21. Moncrieff J, "Magic bullets for mental disorders : the emergence of the concept of an"antipsychotic"drug", J Hist Neurosci, 22, pp.30~46 (2013)
22. Hasse HJ, "Definition and mode of action of the psychomotor Parkinson syndrome therapeutically induced by serpasil and largactil", Monatsschr Psychiatr Neurol, 131, pp.201~214 (1956)
23. Haase HJ, "The Action of Neuroleptic Drugs: a Psychiatric, Neurologic and Pharmachological Investigation" (1965), Yearbook Medical Publishers
24. Delay J, "A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses", Ann Med Psychol(Paris), 118, pp.145~152 (1960)
25. Guttmacher MS, "Phenothiazine treatment in acute schizophrenia; effectiveness : The National Institute of Mental Health, Psychopharmacology Service Center, Collaborative Study Group", Arch Gen Psychiatry, 10, pp.246~261 (1964)
26. Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
27. Tandon R, "Antipsychotic treatment of schizophrenia : two steps for ward, one step back", Curr Psychiatry Rep, 9, pp.263~264 (2007)
28. Crilly J, "The history of clozapine and its emergence in the US market : a review and analysis", Hist Psychiatry, 18, pp.39~60 (2007)
29. Pisciotta AV, "Agranulocytosis following administration of phenothiazine derivatives", Am J Med, 25, pp.210~223 (1958)
30. Anderman B, "Clozapine-induced agranulocytosis : a situation report up to August 1976", Eur J Clin Pharmacol, 11, pp.199~201 (1977)
31. Amsler HA, "Agranulocytosis in patients treated with Clozaril. A study of the Finnish epidemic", Acta Psychiatr Scand, 56, pp.241~248 (1977)
32. Kane JM, "Clozapine for the treatment-resistant schizophrenics", Psychopharmacol Bull, 24, pp.62~67 (1988)
33. Roth BL, "Magic shotguns versus magic bullets : selectively non-selective drugs for mood disorders and schizophrenia", Nat Rev Drug Discov, 3, pp.353~359 (2004)
34. Nucifora FC Jr, "Clozapine as a model for antipsychotic development", Neurotherapeutics, 14, pp.750~761 (2017)
35. Janssen PA, "Pharmacology of risperidone(R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties", J Pharmacol Exp Ther, 244, pp.685~693 (1988)
36. Meltzer HY, "Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and Serotonin2pKi values", J Pharmacol Exp Ther, 251, pp.238~246 (1989)
37. Rebec GV, ""Classical"and"atypical"antipsychotic drugs : differential antagonism of amphetamine-and apomorphine-induced alterations of spontaneous neuronal activity in the neostriatum and nucleus accumbens", Pharmacol Biochem Behav, 11, pp.529~538 (1979)
38. Meltzer HY, "Clozapine : new research on efficacy and mechanism of action", Eur Arch Psychiatry Neurol Sci, 238, pp.332~339 (1989)
39. Casey AB, "Classics in Chemical Neuroscience : aripiprazole", ACS Chem Neurosci, 8, pp.1135~1146 (2017)
40. butyloxy)-3, 4-dihydro-2(1H)-quinolinone(OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity, "J Pharmacol Exp Ther", 1995, 329~336
41. Mailman RB, "Third generation antipsychotic drugs : partial agonism or receptor functional selectivity", Curr Pharm Des, 16, pp.488~501 (2010)
42. McEvoy J, "Brexpiprazole for the treatment of schizophrenia : a review of this novel serotonin-dopamine activity modulator", Clin Schizophr Relat Psychoses, 9, pp.177~186 (2016)
43. Citrome L, "Cariprazine for the treatment of schizophrenia : a review of this dopamine D3-preferring D3", D2 receptor partial agonist, 2016, pp.10, 109~119
44. Kumar B, "Lumateperone: a new treatment approach for neuropsychiatric disorders", Drugs Today(Barc), 54, pp.713~719 (2018)
45. 민성길, "The Past, Present, and Future of sychopharmacology in Korea", Clinical Psychopharmacology and Neuroscience, 4(1), pp.11~23 (2006), 대한정신약물학회
46. Bahk WM, "Clinical Neuropsychopharmacology", pp.3~11 (2014), Sigma Press
47. Delay J, "Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry", Int Rec Med Gen Pract Clin, 168, pp.318~326 (1955)
48. King C, "What’s in a name? The evolution of the nomenclature of antipsychotic drugs", J Psychiatry Neurosci, 27, pp.168~175 (2002)
49. González Monclús E, "Medio Siglo de Psiquiatría en España", pp.81~83 (1992), ELA
50. Lehmann HE, "Concepts, rationale and research", Psychopharmacology frontiers: second international congress of psychiatry psychopharmacology symposium, pp.21~30 (1959), J & A Churchill Ltd
51. Mapp Y, "Psychopharmacology : II tranquilizers and antipsychotic drugs", Psychosomatics, 3, pp.458~463 (1962)
52. Macaluso M, "Tardive dyskinesia : a historical perspective", J Psychiatr Pract, 23, pp.121~129 (2017)
53. Schonecker M, "Paroxysmal dyskinesia as the effect of megaphen", Nervenarzt, 28, pp.550~553 (1957)
54. Kirkby KC, "Social context and health consequences of the antipsychotics introduction", Ann Clin Psychiatry, 17, pp.141~146 (2005)
55. Shepherd M, "Neurolepsis and the psychopharmacological revolution : myth and reality", Hist Psychiatry, 5, pp.89~96 (1994)
56. Bennett D, "150 years of British Psychiatry, 1841-1991", pp.1991, Gaskell
57. DeGrandpre R, "The cult of pharmacology: how America became the world’s most troubled drug culture" (2006), Duke University Press
58. Carton L, "Off-label prescribing of antipsychotics in adults, children and elderly individuals : a systematic review of recent prescription trends", Curr Pharm Des, 21, pp.3280~3297 (2015)
59. "List of off-label promotion pharmaceutical settlements"[URL]
60. Dean CE, "Psychopharmacology : a house divided", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.1~10 (2011)
61. Carpenter WT Jr, "The heterogeneity of the long-term course of schizophrenia", Schizophr Bull, 14, pp.645~652 (1988)
62. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (2013), American Psychiatric Publishing
63. Frances A, "Psychopharmacology the fourth generation of progress", pp.823~ (1995), Raven Press, Ltd
64. Taylor MA, "Psychopathology in neuropsychiatry : DSM and beyond", J Neuropsychiatry Clin Neurosci, 17, pp.246~249 (2005)
65. Davis JM, "Overview: maintenance therapy in psychiatry: I. Schizophrenia", Am J Psychiatry, 132, pp.1237~1245 (1975)
66. Leucht S, "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and meta-analysis", Lancet, 379, pp.2063~2071 (2012)
67. Remington G, "Antipsychotic dosing : found in translation", J Psychiatry Neurosci, 39, pp.223~231 (2014)
68. Depp C, "Clinical trials : bridging the gap between efficacy and effectiveness", Int Rev Psychiatry, 19, pp.531~539 (2007)
69. Carlsson A, "Effect of chlorpromazine or haloperidol on formation of 3methoxytramine and normetanephrine in mouse brain", Acta Pharmacol Toxicol(Copenh), 20, pp.140~144 (1963)
70. van Rossum JM, "The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs", Arch Int Pharmacodyn Ther, 160, pp.492~494 (1966)
71. Eisenberg L, "Mindlessness and brainlessness in psychiatry", Br J Psy chiatry, 148, pp.497~508 (1986)
72. Bracken P, "Psychiatry beyond the current paradigm", Br J Psychiatry, 201, pp.430~434 (2012)
73. Olfson M, "Essential roles for psychiatry in the era of managed care", Arch Gen Psychiatry, 54, pp.206~208 (1997)
74. Kondej M, "Multi-target approach for drug discovery against schizophrenia", Int J Mol Sci, 19, pp.E3105~ (2018)
75. Dauvermann MR, "Glutamatergic regulation of cognition and functional brain connectivity : insights from pharmacological, genetic and translational schizophrenia research", Br J Pharmacol, 174, pp.3136~3160 (2017)
76. Miyamoto S, "Pharmacological treatment of schizophrenia : a critical review of the pharmacology and clinical effects of current and future therapeutic agents", Mol Psychiatry, 17, pp.1206~1227 (2012)
77. International Schizophrenia Consortium, "Common polygenic variation contributes to risk of schizophrenia and bipolar disorder", Nature, 460, pp.748~752 (2009)
78. Cadinu D, "NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update", Neuropharmacology, 142, pp.41~62 (2018)
79. Nikiforuk A, "Assessment of cognitive functions in animal models of schizophrenia", Pharmacol Rep, 70, pp.639~649 (2018)
80. Preissmann D, "Anxiety modulates cognitive deficits in a perinatal glutathione deficit animal model of schizophrenia", Brain Res, 1648, pp.459~468 (2016)
81. Forray C, "Challenges and opportunities for the development of new antipsychotic drugs", Biochem Pharmacol, 143, pp.10~24 (2017)
82. Keshavan MS, "New drug developments in psychosis : challenges, opportunities and strategies", Prog Neurobiol, 152, pp.3~20 (2017)
83. van Praag HM, "Kraepelin, biological psychiatry, and beyond", Eur Arch Psychiatry Clin Neurosci, 258(Suppl 2), pp.29~32 (2008)
84. Blashfield RK, "Toward a taxonomy of psychopathology : the purpose of psychiatric classification", Br J Psychiatry, 129, pp.574~583 (1976)
85. Insel T, "Research domain criteria(RDoC) : toward a new classification framework for research on mental disorders", Am J Psychiatry, 167, pp.748~751 (2010)
86. Miller R, "Validating concepts of mental disorder : precedents from the history of science", Biol Cybern, 108, pp.689~699 (2014)
87. Esterberg ML, "The psychosis continuum and categorical versus dimensional diagnostic approaches", Curr Psychiatry Rep, 11, pp.179~184 (2009)
88. Lilienfeld SO, "Clashing diagnostic approaches : DSMICD versus RDoC", Annu Rev Clin Psychol, 12, pp.435~463 (2016)
89. Jaspers K, "General Psychopathology" (1963), Manchester University Press
90. Oyebode F, "Sims’ Symptoms in the mind: an introduction to descriptive psychopathology" (2015), Saunders Elsevier

관련 논문AI추천